Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy - Wikidata - awgldk - TriplyDB

Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

http://www.wikidata.org/entity/Q35972736

about

Immunosuppressive and anti-inflammatory properties of engineered nanomaterials Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats Plasmonic nanobubbles rapidly detect and destroy drug-resistant tumors Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Nanotechnology-based approaches in anticancer research Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles.A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.Pilot study on biocompatibility of fluorescent nanodiamond-(NV)-Z~800 particles in rats: safety, pharmacokinetics, and bio-distribution (part III)

P2860

Q27005267-D3B698CB-AB57-4324-A88B-EF68C3AB5493 Q28552112-9BC83513-20DA-489E-AB0D-90A46939FCB6 Q30461227-3424A058-D715-4726-9588-3544F2536AF9 Q36011368-89A54F48-00D5-4BCB-8BD6-675BF74BA3C7 Q36168983-407BBD66-81C6-4747-B6ED-FCC6A3BF42A6 Q36319058-B6D0E1D3-A4CC-4CAD-A8E4-E9351A2B1084 Q37228071-9934F974-4B2A-47C0-8A53-4AFE78B472AD Q38141564-35BE3D23-3691-42D7-8F96-8F923A18D9DE Q57074406-D645AA52-80D7-4CC8-A4FF-FF22613180D8

P2860

Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

http://www.wikidata.org/entity/Q35972736

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@ast

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@en

type

label

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@ast

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@en

prefLabel

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@ast

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@en

P1433

Q35972736-C921BF31-9EFE-496E-8822-B93096C6F932

P1476

Q35972736-821EA0B8-65FF-4BFB-8761-9BB81922FCF0

P2093

Q35972736-25F843E2-90AE-42A9-90B8-4697C3EFE0EB

Q35972736-495B75F3-5DB9-451F-9F1F-1A0AD7805E59

Q35972736-5A0EF1DE-3B74-4B17-B5DA-410CEB902888

Q35972736-64ACC27D-E7AD-4DF3-8500-73EE9CB72C2F

Q35972736-6ED14462-E348-4C73-B7AB-091BE70F22C9

Q35972736-99C3617D-B775-4EBE-A671-11D4320E8359

Q35972736-9B6BC6DA-CF86-4E0F-8EA0-0420EA88E356

Q35972736-9D097094-3FD3-4421-8AA6-6C7D0CBDDB53

Q35972736-A1F86A82-E5E9-42E2-8D5E-07435BEC5A58

Q35972736-B65EA1B0-59C3-40E0-BC4C-F94C1C27635E

P2860

Q35972736-02E02CCC-6DB4-465B-ABF1-5F04A1808C73

Q35972736-189C47C6-453E-4C9C-A82A-95865416F6F6

Q35972736-1E038B36-9C22-4DAD-B44F-C035F1923DD3

Q35972736-22E08EAD-21B9-40E3-9FE2-23168BF0743D

Q35972736-26C60CE9-F25C-4F0F-A8E9-429C4328EC1E

Q35972736-49E6C913-86C1-40BD-819F-BDB32B4B2DAB

Q35972736-5242711D-8A1A-4C03-83AE-12208DDF4E72

Q35972736-52E3C770-8DD3-485D-9BB3-B8B6CB4C95A5

Q35972736-59B93276-A1BE-44D6-8E41-F8E2CBDCEE42

Q35972736-6B244906-90E7-45B5-AC7B-E53EDEBD11C9

P304

Q35972736-CC0F9B44-55F9-42C7-9544-9047D7A36A58

P31

Q35972736-7A06AF67-7428-415C-852D-874535C5915B

P356

Q35972736-2ACD1DB1-CBDF-4A8D-BB47-732733D5626D

P407

Q35972736-B35614FE-3DC6-4030-9EC0-808DAC0F88AF

P478

Q35972736-78C94CB2-5786-4670-B6EF-34152D9766BA

P577

Q35972736-611C9FE2-35FE-48E2-ACD7-27E527BAE545

P5875

Q35972736-ADF5C4C4-BC9F-4D1B-9C0F-CC2D8684013B

P698

Q35972736-A65AABF1-95B6-4A03-822E-2312EAE811CD

P921

Q35972736-A9CCF6DA-1BB9-41A3-87CE-E134E645E171

P932

Q35972736-A7FF893E-B4DA-4CEF-8A88-4547C1797B55

P356

P1433

International Journal of Nanomedicine

P1476

Preclinical evaluation of inje ...... anoparticle for cancer therapy

@en

P2093

Eun Jin Ju

http://www.w3.org/2001/XMLSchema#string

Eun Kyung Choi

http://www.w3.org/2001/XMLSchema#string

Ha Na Woo

http://www.w3.org/2001/XMLSchema#string

Heon Joo Park

http://www.w3.org/2001/XMLSchema#string

Hye Kyung Chung

http://www.w3.org/2001/XMLSchema#string

Hye-Won Kang

http://www.w3.org/2001/XMLSchema#string

Jin Seong Lee

http://www.w3.org/2001/XMLSchema#string

Joohee Jung

http://www.w3.org/2001/XMLSchema#string

Jung Shin Lee

http://www.w3.org/2001/XMLSchema#string

Min-Hyo Seo

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the role of mTOR in cancer

Cancer nanotechnology: opportunities and challenges

Nanocarriers as an emerging platform for cancer therapy

mTOR and cancer: insights into a complex relationship

Drug delivery systems: entering the mainstream

Solubilization of rapamycin.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.

Rapamycin: clinical results and future opportunities.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

P304

2197-2208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJN.S29480

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225042308

http://www.w3.org/2001/XMLSchema#string

P698

22619555

http://www.w3.org/2001/XMLSchema#string

P921

P932

3356221

http://www.w3.org/2001/XMLSchema#string